Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash & Equivalents (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Cash & Equivalents for 8 consecutive years, with $145.7 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 408.2% to $145.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $145.7 million through Dec 2025, up 408.2% year-over-year, with the annual reading at $145.7 million for FY2025, 408.2% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $145.7 million at Whitehawk Therapeutics, up from $37.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $227.6 million in Q1 2025, with the low at $28.7 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $89.2 million, with a median of $65.5 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents crashed 73.81% in 2022, then surged 408.2% in 2025.
  • Over 5 years, Cash & Equivalents stood at $149.0 million in 2021, then plummeted by 73.81% to $39.0 million in 2022, then soared by 61.17% to $62.9 million in 2023, then tumbled by 54.41% to $28.7 million in 2024, then soared by 408.2% to $145.7 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $145.7 million, $37.9 million, and $177.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.